Clinical and immunological efficacy of the Leyargunal in chronic respiratory diseases

Smirnova A., Novikov D., Janchanka U.

Vitebsk State Medical University, Belarus

Objective. A clinical and immunological research study of Leyargunal (L-Leucine 1000 mg, L-Arginine hydrochloride 600 mg and Inosine 400 mg) and Placebo for the treatment of chronic obstructive pulmonary disease (COPD), and COPD with non-allergic moderate asthma (COPD + BA).
Material and methods. We performed a double-blind, placebo-controlled trial of the treatment with Leyargunal in 60 patients with COPD and COPD + BA. The number and total period of exacerbations, duration of inpatient hospitalization, and the duration of remission (time frame: 12 months) were taken into consideration as primary outcome. Secondary outcome consisted of the clinical analysis of blood, blood chemistry, clusters of differentiation lymphocytes (CD3, CD4, CD8, CD13, CD14, CD16, CD22, CD25, CD34, CD38, CD69, CD71), levels of the immunoglobulins, cytokines (IFNg, IFNa, IL-1b, IL- 2, IL- 4, IL- 6, IL- 12, TNF-a, TGF-b1) and phagocytosis.
Results. There was an increase in the duration of remission (p = 0.021) and decrease in the number of exacerbations (p = 0.042) for Leyargunal treated patients with COPD and COPD + BA. In the group with COPD + BA a reduction in the expression of activation markers CD38+ and CD71+ was observed; as well as a reduction in the number of CD34+ cells, a decrease in the IFNg level, and an increase in IL-6 and IL4 level. In the group of patients with COPD, a decrease of CD13+ and CD14+ lymphocytes was observed. Level of IL-1b during treatment increased and then decreased in two months. In patients with COPD the number of CD34 + increased.
Conclusion. Our data show the clinical and immunological efficacy of treatment by Leyargunal of the patients with chronic broncho-pulmonary pathology.